Alipay Aims to Help 10 Million European Merchants Reach Over 2 Billion Potential Consumers in Five Years With Innovative Technology
14.11.2019 14:08:00 EET | Business Wire | Press release
Alipay, the world’s leading payment and lifestyle platform, today announced a new target to support 10 million small and medium enterprises in Europe over the next five years, through innovative technology that will empower these merchants to better serve and sell to over 2 billion potential consumers travelling to the region from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005332/en/
A Chinese tourist uses Alipay to pay for items at a store in Norway. (Photo: Business Wire)
The strategy to support these merchants was unveiled today during the Alipay Partners Global Summit held in London. This includes an expanded collaboration with the largest European acquirer Worldline, as well as a new initiative to serve airport shops around the world through in-app mini programs.
“Our aim is to improve the way in which individuals and businesses buy, sell and receive payments, and to do this, we need to draw upon the strength of our partnerships,” said Eric Jing, Chairman and CEO of Ant Financial, operator of Alipay. “Our growth has only been possible due to the network of partners we have established, and working together, we will make it easier for anyone to do business anywhere.”
“Our innovative solutions will continue to help merchants in Europe better serve the growing numbers of tourists as well as e-commerce shoppers coming to the region from all over the world,” Eric said.
Alipay is China's most popular digital payment service, according to market researcher Statista, with 87 percent of survey respondents in the country aged between 18 and 69 reporting that they use Alipay for their digital financial needs. Alipay currently serves over 1.2 billion users together with local e-wallet partners in the Republic of Korea, Thailand, Malaysia, the Philippines, Indonesia, India, Bangladesh, and Pakistan.
Alipay is continually working with its partners around the world, leveraging technology to build a seamless ecosystem that allows merchants to better serve their customers, which will in return help boost their sales.
In a report published this year, Nielsen found that over 93% of Chinese tourists would be more willing to make purchases with their mobile phones and would even increase their spending if the option were available, while 60% of merchants surveyed that adopted Alipay reported growth in foot traffic and revenue.
Currently, Alipay collaborates with more than 120 financial institutions in Europe and is constantly adding more and more partnerships with travel service agencies and other types of third-party service providers. This will help merchants deliver enhanced experiences to their customers as they seize the growth opportunities in the global travel market.
More details on the new innovations unveiled today by Alipay:
- The first is the expanded partnership with Worldline, an existing acquirer for Alipay that will work with Alipay’s e-wallet partners from Asia for the first time, allowing European merchants to accept payments from them through their Alipay-enabled points of sale. This multi-wallet acceptance means merchants across Europe will be able to drive increased footfall and spending from tourists from across Asia.
-
Additionally, Alipay has developed mini programs to enhance tourists’ experience at airports around the world, offering services such as convenient payments and personalized recommendations. Alipay Mini Programs officially launched in July 2018, opening up the service to independent programmers and enterprises to create interesting and useful “lite apps”.
- How it works: The first airport mini program was launched by Hong Kong International Airport, allowing orders to be fulfilled as quickly as 90 minutes from ordering, so travellers can shop online and buy at their leisure, well before they reach the airport, and pick up their duty-free purchases as soon as they arrive.
- Additional features: The tailor-made airport mini program provides a range of services including flight information, transfer and entry tips, and other practical features including an instant chat within the mini program. It is also embedded with Alipay’s scenario solutions such as online transportation reservation and scan to order dining, as well as reminders of estimated time through security and boarding notices just by inputting flight details. Users can also receive electronic coupons and membership benefits offered by Alipay, as well as one-stop information and optimised route recommendations in the airport, allowing them to enjoy the airport’s services with ease.
About Alipay
Operated by Ant Financial Services Group, Alipay is the world’s leading payment and lifestyle platform. Launched in 2004, Alipay serves over 1.2 billion users with its local e-wallets partners as of June 2019. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Alipay’s in-store payment service covers over 50 markets across the world, and tax reimbursement via Alipay is supported in 35 markets. Alipay works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites. Alipay currently supports 27 currencies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191114005332/en/
Contact information
Media Inquiries
Yang Xinyun
Ant Financial
+8613816896301
xinyun.yang@antfin.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
